THE ONLY SYSTEM^ CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA

MINIMED® 640G systEM^ wIth sMartGuarD™ tEchNoloGy

HCP BROCHURE.v7.indd 1 18/07/2016 2:06 PM

HYPOGLYCAEMIA IS CHALLENGING FOR GLYCAEMIC CONTROL1 AND quALITY OF LIFE2

Achieving good glucose control without the risk or fear of going low is a challenging balancing act for you and your patients.

POOR GLYCAEMICCONTROLProvIDEs rIsk for both DEvEloPMENt aND ProGrEssIoN of DIabEtEs coMPlIcatIoNs.5

of sEvErE hyPoGlycaEMIc EvENts lEaD toSEIzURES & COMA.

26% 4

oN avEraGE a PatIENt EXPErIENcEs 74%

Of TYPE 1PatIENts rEPort altErING INsulIN DosEs out of fEar of hyPoGlycaEMIa.3

SYMPTOMATIC HYPOS PER WEEK. 1

HCP BROCHURE.v7.indd 2 18/07/2016 2:06 PM

“ Hypoglycaemia is the biggest barrier to good glycaemic control in patients with type 1 diabetes. It causes fear and worry for patients and is costly to our healthcare budgets.” Dr Conget

38% of EMErGENcy MEDIcal sErvIcE call outs for hyPoGlycaEMIa rEsult IN hosPItalIsatIoN.6

Patients with severe hypoglycaemia have a greater fear of hypos, more diabetes-related distress and poorer general emotional wellbeing.3

HCP BROCHURE.v7.indd 3 18/07/2016 2:06 PM

75% Of SMARTGUARD EVENTS DID NOTHIT THE LOW GLUCOSE LIMIT.8

Based upon SmartGuard real life data from 4,818 patients*

SmartGuard, our exclusive closed loop technology, provides protection against hypoglycaemia.8 It can:

HELP PREVENT SEVERE HYPOGLYCAEMIC EPISODES

automatically stops insulin when sensor glucose is predicted to approach a pre-set low limit.

HELP AVOID HYPERGLYCAEMIC REbOUNDresumes insulin delivery when levels recover.

HELP PROVIDE bETTER PROTECTION AGAINST LOWSallows your patients to set multiple low limits throughout the day and night.

MINIMED 640G SYSTEM^ WITH SMARTGuARD PROVIDES ADVANCED PROTECTION AGAINST HYPOGLYCAEMIA7

HCP BROCHURE.v7.indd 4 18/07/2016 2:06 PM

TRuST SMARTGUARD TO DO THE WORk

Sensor Glucose values associated with automatically-resumed events showed less glycaemic variability than those associated with manually-resumed events.7

Trust our accurate system to provide Advanced Protection for your patients (9.1% MARD).9

SmartGuard technology provides advanced protection from hypoglycaemia without significant increase in hyperglycaemia.1

* Medtronic data on file: SmartGuard technology real life data evaluated using the voluntary MiniMed 640G system uploads to CareLink Personal from Jan. 13th 2015 to Jan. 14th 2016.

SMARTGUARD REAL LIfE PERfORMANCE DATA*

NO INCREASE IN HYPERGLYCAEMIA

LESS GLYCAEMIC VARIAbILITY

Glu

cose

mg/

dL

With SmartGuard Without SmartGuard

-120 -60 0 60 120 180 240 300 360

Time from event start (minutes)

Insulin suspended

Low limit

High limit

Low limit

predicted

1:00

SmartGuard suspends insulinwhen sensor glucose is approaching a pre-set low limit.*

1:30 2:00 2:30 3:00 3:30 4:00 4:30

Time of day (AM)

Sen

sor G

luco

se m

mo

l/L

SmartGuard resumes basal insulin Delivery will automatically resume if sensor glucose recover.**

predicted

On

Off

On

Off

SmartGuard feature:

SmartGuard feature:

2.3

3.4

4.5

5.6

6.7

6674891:;<=5>?1@AA1#*1B5/C5>0345

0

50

100

150

200

250

300

0

200

400

600

800

200

-2 -1 0 1 2 3 4 5 6

Time from the Suspend event (hr)

0

6.0

4.0

2.0

8.0

10.0

12.0

Sen

sor G

luco

se m

mo

l/L

HCP BROCHURE.v7.indd 5 18/07/2016 2:06 PM

“ The MiniMed 640G system^ with SmartGuard significantly reduces hypoglycaemia in clinical practice and allows more time to be spent within target glycaemic range.”

Glu

cose

mg/

dL

With SmartGuard Without SmartGuard

-120 -60 0 60 120 180 240 300 360

Time from event start (minutes)

Insulin suspended

Low limit

High limit

Low limit

predicted

1:00

SmartGuard suspends insulinwhen sensor glucose is approaching a pre-set low limit.*

1:30 2:00 2:30 3:00 3:30 4:00 4:30

Time of day (AM)

Sen

sor G

luco

se m

mo

l/L

SmartGuard resumes basal insulin Delivery will automatically resume if sensor glucose recover.**

predicted

On

Off

On

Off

SmartGuard feature:

SmartGuard feature:

2.3

3.4

4.5

5.6

6.7

6674891:;<=5>?1@AA1#*1B5/C5>0345

0

50

100

150

200

250

300

0

200

400

600

800

200

-2 -1 0 1 2 3 4 5 6

Time from the Suspend event (hr)

0

6.0

4.0

2.0

8.0

10.0

12.0

Sen

sor G

luco

se m

mo

l/L

HOW SMARTGUARD WORkS

*The dynamic suspend feature is based on certain criteria: sensor glucose must be within 3.9mmol/L of the low limit and predicted to be 1.1mmol/L above the low limit within 30 minutes AND the pump must not be in the refractory period. **The dynamic resume feature is based on certain preset criteria: sensor glucose must be 1.1mmol/L above the preset low limit andpredicted to be 2.2mmol/L above within 30 minutes AND insulin must have been suspended for at least 30 minutes.

HCP BROCHURE.v7.indd 6 18/07/2016 2:06 PM

MINIMED 640G SYSTEM^ GREATER CONVENIENCE IMPROVED DESIGN

Diabetes is already complicated, your patients’ system shouldn’t be.

* Calculation is based on the amount of insulin currently in the body, the amount of carbohydrates, the user’s current and target blood sugar levels, their insulin-to-carb ratio and their body’s sensitivity to insulin. Proper Bolus Wizard setup must be completed first. Users must input the number of carbohydrates their current blood glucose value before the Bolus Wizard can calculate the insulin users.

** Waterproof at time of manufacture up to 3.6 meters for up to 24 hours at a time. See MiniMed 640G User Guide for a complete description of the waterproof capabilities and proper use instructions.

GREATER CONVENIENCE Greater and easier dosing for patients with the Bolus Wizard™ calculator.*

Preset bolus options, personalised basal patterns and programmable reminders for easy customising of your patients’ therapy.

IMPROVED DESIGN Intuitive10 navigation for easy training.

Waterproof** allowing uninterrupted wear.

Full-colour, auto-brightness display for legibility even for patients with reduced eyesight.

HCP BROCHURE.v7.indd 7 18/07/2016 2:06 PM

Medtronic Australasia Pty Ltd, 97 Waterloo Road, North Ryde NSW 2113 Australia

Mail: Medtronic Diabetes, PO Box 945, North Ryde, NSW 1670

24-hour Toll Free: 1800 777 808

australia.diabetes@medtronic.com

facebook: www.facebook.com/MedtronicDiabetesAuS

Instagram: @MedtronicDiabetesAus

YouTube: Medtronic Diabetes ANZ

https://hcp.medtronic-diabetes.com.au

MINIMED 640G systEM^ wIth sMartGuarD tEchNoloGyIT THINKS

Safety Information: MiniMed 640G

MiniMed™ 640G Insulin Pump system is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. In addition, the pump system is indicated for continuous or periodic monitoring of glucose levels in the fluid under the skin, and possible low and high glucose episodes. When using a sensor and transmitter, the pump displays continuous glucose values and stores this data so that it can be analyzed to track patterns and improve diabetes management. Pump history can be downloaded to a computer for analysis of historical glucose values. The continuous sensor glucose values provided by the MiniMed™ 640G insulin pump system are not intended to be used directly for making therapy adjustments. Rather, they provide an indication that a confirmation fingerstick measurement may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not based on the value displayed by the pump. For listings of indications, contraindications, precautions, warnings and parental adverse events, please refer to the instructions for use. MiniMed™ 640G, SmartGuard™, Bolus Wizard™, Guardian 2 CareLink and Enlite are Trademarks of Medtronic Inc. Bayer®, Bayer Cross® are trademarks of Bayer. Ascensia and CONTOUR are trademarks of Ascensia Diabetes Holdings AG.

Please visit www.medtronicdiabetes.com/importantsafetyinformation for complete details. APPROVAL #3105-062016 Date of prep: April 2016

1 Cryer, PE. Diabetologia. 2002, Jul 45(7):937-48. 2 Hendrieckx, C. et al. Diabetes Research and Clinical Practice 2014. 3 Fidler, C. et al. J Med Econ. 201114(5)646-655. 4 DCCT Group. N Engl J Med. 1993 Sep; 329:977-986. 5 Skyler, JS. Edocrinol Metab Clin North Am. 1996 Jun; 25(2)243-54. 6 Villani, M. et al. Journal of Diabetes and its Complications. 2016. 7 Choudhary, P. et al. Diabetes Technol. Ther. 2016, Vol 18 (5). 8 Medtronicdata on file: SmartGuard real life data. Medtronic MiniMed evaluated using the voluntary MiniMed 640G uploads to CareLink Personal from Jan. 13th 2015 to Jan. 14th 2016. 9 Cohen, O. et al. Diabetes Technol.Ther. Feb 2016, 18(S1): A-81-82. 10 CCR Study, 2012 HFMD, Inc. Data on file at Medtronic MiniMed, Inc. Northridge, CA. 11 Bailey, T. et al. Clin Chim Acta 2015 Aug; 448:139-45. 12 In vitro diagnostic test systems-requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus. Geneva, Switzerland: International Organization for Standardization; ISO 15197:2013.‡When combined with the MiniMed 640G system and Guardian 2 Link transmitter. ^components sold separately

INSULIN DELIVERYMedtronic offers a wide range of infusion sets so that you can choose the right infusion set for your patients’ comfort and safety.

THERAPY MANAGEMENT TOOLS CareLinktM Pro software includes insightful trend reports and therapy considerations to help you make informed treatment decisions for your patients.

CONTINUOUS GLUCOSE MONITORING the Enlite™ sensor provides a reliable9 CGM experience for your patients.‡1

bLOOD GLUCOSE TESTING contour™Next lINk 2.4 meter links wirelessly to MiniMed 640G and provides proven11,12 testing accuracy and discreet remote bolusing.

HCP BROCHURE.v7.indd 8 18/07/2016 2:07 PM